JAMA

Fairness audits of chest radiograph artificial intelligence usually score subgroup performance against labels extracted from radiology reports by natural language processing (NLP). We tested whether these labels can make a model look fairer than it is, a failure we call phantom fairness. On 4,376 NIH ChestX-ray14 images with both NLP and radiologist-adjudicated labels, we audited classifiers from three backbones by sex, age, projection and older women. NLP labels missed 54% to 59% of radiologist-confirmed airspace opacity, pneumothorax and nodule or mass, and every fracture. These misses were not random: models scored them lower than NLP-caught positives for every finding and backbone (median rank-biserial correlation 0.20 for the primary backbone and 0.16 for the others; all adjusted p [≤] 0.038), so the labelling errors hid the models' own mistakes. Subgroup gaps were larger on adjudicated labels in 16 of 24 comparisons, none individually significant. For pneumothorax in women older than 60 years, the NLP audit showed a sensitivity gap of 0.064 against a true gap of 0.184; removing the hardest positives reproduced this concealment (0.124 against 0.120 observed), whereas random label errors produced less (0.077). Fairness audits based on NLP-extracted labels should be treated as provisional until checked against radiologist-adjudicated labels.

Background: Papillary thyroid microcarcinoma (PTMC, equal to or smaller than 1 cm) is increasingly diagnosed, and a subset behaves aggressively. Preoperative ultrasound (US) and fine needle aspiration (FNA) accuracy in this size range, particularly with multinodular disease, is poorly defined outside East Asian screening cohorts. Materials and Methods: We retrospectively analyzed 180 consecutive PTMC cases (2017 to 2026) with preoperative US and FNA and compared them with 191 benign thyroidectomy controls. ROC analysis identified an optimal size cutoff. We compared sensitivity, specificity, PPV, NPV, and accuracy across tumor-size subgroups, before/after 2023, and with/without dominant nodules (DNs) equal to or larger than 2 cm. Results: ROC analysis identified 5 mm as the optimal cutoff (AUC 0.80). FNA sensitivity was 44.4% overall, falling to 14.1% for tumors <5 mm versus 61.2% for [&ge;]5 mm, with specificity uniformly high (94.8%). US showed a similar pattern (sensitivity 23.4% vs. 64.7%) but lower specificity (69.6%), driven largely by calcification and Hashimoto's-related hypoechogenicity. Combined FNA+US improved sensitivity to 59.4%. DNs equal to or larger than 2 cm markedly reduced FNA true-positive rates (67.9% vs. 10.8%; OR 17.4). Excluding DN cases raised FNA sensitivity to 67%, NPV to 84.2%, and accuracy to 85.2%. Post-2023 experience significantly improved all metrics (sensitivity 34.4% to 54.4%). Conclusion: FNA and US sensitivity for PTMC decline sharply below 5 mm and in multinodular glands with dominant nodules, while specificity/PPV remain high. A 5 mm threshold, operator experience, and selective avoidance of FNA in dominant-nodule bearing multinodular goiters (favoring direct surgical referral) can meaningfully improve diagnostic performance and guide management.

BACKGROUND Extensive research has documented medication abortion safety. Large-scale insurance claims data offer an important complement to clinical studies by assessing real-world outcomes in routine practice. In claims data, researchers must infer mifepristone use, clinical outcomes, and event severity from diagnosis, treatment, and utilization codes. Understanding how these analytic choices influence safety and effectiveness estimates is important for interpreting evidence used to inform care delivery and medication policy. METHODS We conducted a retrospective cohort study of mifepristone use with national multipayer claims data, both medical and pharmacy, from 2017 through 2023. We identified both a broad cohort and a more specific medication-abortion cohort after excluding evidence of other indications. We classified potential safety events, effectiveness outcomes, and health care utilization within 45 days of mifepristone use. Serious adverse events required claims-observable consequences consistent with FDA seriousness criteria. RESULTS The broad cohort included 869,409 mifepristone uses among 698,780 unique patients for medication abortion or other indications. After restriction to uses with additional evidence of medication abortion, 775,931 uses among 626,443 unique patients remained. In the medication-abortion cohort, 3,306 uses were followed by at least one serious adverse event, resulting in an absolute 45-day risk of 0.43%. Serious bleeding or hemorrhage occurred after 0.24% of uses, serious infection or sepsis after 0.05%, serious hypersensitivity or anaphylaxis after 0.01%, and serious ectopic-pregnancy outcomes after 0.05%. CONCLUSIONS Serious adverse events after mifepristone use were rare in this national study. Applying established, clinically grounded criteria markedly reduced the number of events classified as serious.

Background: The relationship between recent viral infection and subsequent susceptibility to, or protection against, other viruses remains unclear, particularly across ages and symptom status. Methods: A prospective cohort study enrolled participants aged 6 months to 49 years in Washington and Oregon, USA, 2022-2024. Weekly nasal swabs were tested for SARS-CoV-2, respiratory syncytial virus (RSV), and influenza A/B; additional swabs were collected during symptomatic illness and were also tested for parainfluenza (PIV) 1-4, endemic human coronaviruses (hCOV), adenovirus, human metapneumovirus, human rhinovirus (hRV), and enteroviruses. Proportional hazards regression models were used to characterize associations between incident symptomatic infection (illness) and history of recent illness due to other viruses (within 1-7, 8-14, 15-30, 31-60, 61-90, 91-180 days), adjusted for geographic region, age, sex, daycare/school/work attendance, household size, and number of children in the household. For SARS-CoV-2, influenza, and RSV, these analyses were repeated to study incidence of infection (including asymptomatic cases). Findings: Of 3,560 participants, 2,969 (83%) had [&ge;]1 illness over 4,299 person-years. Adjusted hazard ratios (aHRs) in the short term ([&le;]2 weeks) after an illness were predominantly below 1, indicating that recent viral illness was often associated with lower risk of subsequent illness with other viruses. Across age groups, recent hRV illness was associated with lower risk of hCOV, PIV, and RSV illness (aHRs 0.07-0.27). SARS-CoV-2 illness was associated with a higher short-term risk of adenovirus and PIV illness (aHRs 3.20-3.33). In children aged 6 months-4 years, recent influenza illness was associated with higher short-term risk of SARS-CoV-2 illness. Including asymptomatic infections generally attenuated these associations. Interpretation: Some viral illnesses may alter short-term susceptibility to subsequent viral illnesses. Interactions may differ by age and symptom status. Funding: US Centers for Disease Control and Prevention; Washington State Department of Health.

Objective. Temperature readings are routinely stratified by race and ethnicity, though significant group differences may reflect physiology, instrument noise, or categorization rather than biology. This study tests whether these categories partition facial infrared thermography measurements beyond individual variation and baseline device noise. Approach. A secondary analysis of thermography data (n = 951 adults) compares inner-canthus maximum (TCEmax) and full-face maximum (Tmax) temperatures across five administrative categories via one-way analysis of variance (ANOVA), mixed-effects modeling, Bland-Altman analysis against oral reference, and Monte Carlo sensitivity analysis. Main results. ANOVA returns significant group differences (p < 0.001; eta-squared = 0.04 for TCEmax, 0.03 for Tmax), but the total spread (0.2 to 0.3 degrees Celsius) is comparable to device accuracy and within-subject variability. Individual variation accounts for 95% of TCEmax variance, and adding simulated Gaussian noise to participant-level temperatures (sigma = 0.10 to 0.30 degrees Celsius) preserves the complete group-mean rank order in as few as 37.5% of iterations. Significance. Testing whether a group difference survives perturbation at the scale of instrument accuracy offers a check against treating significance alone as evidence of physiology. Here, observed group differences are small relative to measurement variability, and their physiological interpretation remains uncertain, with implications for clinical tools that treat administrative categories as biologically meaningful.

ObjectivesTo determine whether single-layer evaluation characterises clinical risk in the final note of a multilingual ambient AI scribe, and where serious errors arise. DesignTwo-arm evaluation on one common clinical-risk scale, using a frozen, reference-aligned synthetic corpus. SettingScripted consultations spanning 77 languages and five complexity levels, from simple general practice to expert multidisciplinary-team handover. Main outcome measuresPer-session incidence of at least one serious (HIGH or CRITICAL) note-layer error in intrinsic (reference script to note, n=385) and end-to-end (automatic speech recognition (ASR) transcript to note, n=2,302) generation; three LLM raters classified discrepancies using a four-mode taxonomy. ResultsIntrinsic note generation had a 3.4% serious-error rate, with no detectable gradient across complexity (1% to 6%; Cochran-Armitage p=0.42) or language resource (high 2%, medium 5%, low 4%). End-to-end serious errors rose steeply with complexity (L1 1% to L4/L5 24%) and language scarcity (high 7%, medium 10%, low 15%; OR 1.54 per tier, 95% CI 1.15-2.07; p=0.004, GEE clustered on language). Of serious in-note errors, 87% were ASR-derived and 7% note-originated; amplification exceeded correction threefold (fate entropy 1.19 bits). Repeated generation showed moderate reproducibility (Fleiss kappa 0.42); word error rate explained 24% of cross-language variance versus [~]1% for transcription risk density. ConclusionsLow serious-error rates in individual layers did not preclude higher end-to-end note risk. Evaluation should therefore include the clinician-facing note, because component-level metrics cannot fully capture risk created or transformed at the transcription-to-generation interface. What is already known on this topicO_LIAmbient AI scribes are being deployed globally, and safety evaluation has characterised the transcription layer in isolation, most commonly with word error rate C_LIO_LIFrequency-based transcription metrics such as word error rate do not directly encode clinical consequence, and component-level performance may not represent the risk of the final generated note C_LIO_LILarge language models produce clinically relevant output stochastically, so identical prompts can yield materially different content C_LI What this study addsO_LINote generation from a perfect transcript had a low observed serious-error rate and no detectable complexity or language-resource gradient, whereas the end-to-end system showed steep gradients on both axes. C_LIO_LISerious note-layer errors were predominantly ASR-derived, but note generation transformed upstream errors variably, amplifying serious errors about three times more often than it corrected them C_LIO_LITranscription-layer metrics had limited predictive value for note-layer risk after accounting for complexity and language-level dependence; word error rate explained approximately one-quarter of cross-language variance C_LI How this study might affect research, practice or policyO_LIEvaluation and procurement of ambient scribes should include end-to-end assessment of the clinician-facing note, with results stratified by consultation complexity and language where relevant C_LIO_LIA three-surface root-cause alignment using a four-mode root-cause taxonomy (note-originated, propagated-ASR, amplified-ASR and silent-correction) can attribute documentation errors to their point of origin or transformation C_LIO_LILanguage-related performance should remain a surveillance target because disparities can emerge after components are composed, even when corresponding gradients are not detectable in an individual layer C_LI

Background: Pregnancy is a uniquely complex ethical and clinical context in which precision medicine approaches, including genomics-driven risk prediction tools, biomarker-based stratification, and data-intensive analytics, are rapidly evolving. There is a need for community consultation on the ethical, social, and practical implications of precision medicine in pregnancy research and healthcare. Aim: The primary aim of this study was to engage healthcare consumers to build consensus on the acceptability of precision medicine approaches in pregnancy research and healthcare. We also sought to identify consumer priorities for future research. Methods: A two-round modified Delphi study was conducted to determine consumer opinions on the use of precision medicine approaches in pregnancy research and healthcare. Seven in-person workshops (round one) were held, with purposeful recruitment to ensure a representative group of healthcare consumers who engage with the healthcare system during pregnancy. These included first-time parents, culturally and linguistically diverse women, Aboriginal and Torres Strait Islander women, and women and their partners who had experienced previous pregnancy complications. Recruitment was conducted through established advocacy networks, and each workshop was facilitated by representatives from each organization. A second-round online survey, based on workshop content, was completed to assess the acceptability of precision medicine and to determine consumer priorities for future precision medicine research on pregnancy health. Results: Precision medicine research and the implementation of new technologies in clinical care were acceptable to participants; however, the need for transparency and trust between participants and researchers regarding the use and storage of genetic material was highlighted, particularly among Aboriginal and culturally and linguistically diverse participants. Outcomes related to survival and perinatal complications (stillbirth, preterm birth, and labor complications) were the highest-rated consumer research priorities, along with maternal mental health and breastfeeding. When asked whether participants would like to see PM available as part of routine pregnancy care for conditions with available treatments, complete consensus (100%) was reached. Conclusion: Healthcare consumers strongly support the use of precision medicine in pregnancy research and its translation into routine clinical care, particularly when effective interventions are available. However, implementation must be underpinned by transparency, trust, culturally appropriate governance, and clear communication about the collection, storage, and use of genetic material. These findings provide a consumer-informed framework for prioritizing future precision medicine research and guiding its responsible translation into pregnancy care.

Background: Patients increasingly consult free artificial intelligence (AI) chatbots about their symptoms, but these models may favour agreement with the patient over accuracy. In obstructive sleep apnoea (OSA), where most cases in the general population remain undiagnosed and diagnosis depends on referral, this could validate symptom denial. We tested whether consumer chatbots maintain guideline-concordant referral when a simulated patient minimises symptoms. Methods: Seven guideline-concordant and standardised OSA vignettes (apnoea-hypopnoea-index, AHI 8-52 events/h; body mass index 28-42 kg/m2) were presented to five free chatbots (GPT-5, Gemini 2.5 Flash, Claude Sonnet 4.6, DeepSeek V4 Flash and Grok-4.3) under neutral and symptom-minimising conditions (10 simulated conversations per model-vignette-condition cell; N=700). Referral maintenance was scored by a structured rubric and every capitulation was human-confirmed. Results: All chatbots maintained referral recommendations in neutral conversations (350/350; 100%). When simulated patients minimised symptoms and resisted referral, maintenance fell to 64.3% (225/350), a reduction of 35.7 percentage points (95% CI 5.5-66.0; p=0.028). Rates ranged from 55.7% to 85.7% across chatbots, but evidence of between-chatbot differences was inconsistent across analyses. Rates differed across clinical vignettes (p=0.001). A variance analysis estimated greater variation between vignettes than between chatbots. In the three driving-risk vignettes, referral recommendations were abandoned in 46-68% of symptom-minimising conversations, pooling all five chatbots within each vignette. Conclusions: Consumer AI chatbots abandoned correct OSA referral recommendations in about one-third of symptom-minimising conversations, with higher observed abandonment in simulated cases involving driving risk. This may delay appropriate assessment and raises patient- and public-safety concerns.

This was a cohort study of 1,663 subjects (1196 women, 467 men; median age 48 years, IQR 37-57) with thyroid nodules recruited from 2020 to 2025 in five tertiary medical centers. Cytological/histopathological diagnoses were established by an independent review committee, and preoperative serum thyroid hormone metabolites (THMs) were tested using liquid chromatography tandem mass spectrometry. A diagnostic model on this serum THM test to distinguish between differentiated thyroid cancer (DTC) and benign thyroid nodule (BTN) was trained on 872 retrospective subjects (454 DTC and 418 BTN), followed, prospectively, by model validation on 392 subjects (195 DTC and 197 BTN) and a second validation on 399 subjects (300 DTC and 99 BTN). Following successful diagnostic model training, the model validation demonstrated a diagnostic specificity of 99.5% (196/197), sensitivity of 92.3% (180/195), positive predictive value (PPV) of 99.4%, negative predictive value (NPV) of 92.9%, and diagnostic accuracy of 95.9% (95% CI, 90.8 to 100.0%) for DTC. Combination of the two validation cohorts showed a diagnostic specificity of 99.7% (295/296), sensitivity of 92.1% (456/495), PPV of 99.8%, NPV of 88.3%, and diagnostic accuracy of 94.9% (95% CI, 91.5 to 98.0%) for DTC. The test on indeterminate Bethesda categories III-IV (139 DTC, 87 BTN) showed a diagnostic specificity of 100.0% (87/87), sensitivity of 93.5% (130/139), PPV of 100.0%, NPV of 90.6%, and diagnostic accuracy of 96.0% (95% CI, 89.2 to 100.0%) for DTC. This study develops a novel molecular blood test of serum THMs for preoperative diagnostic evaluation of thyroid nodules, which displays a high PPV and decent NPV with an excellent overall diagnostic accuracy for DTC.

Objectives. Observational studies report large, conflicting associations between common drugs and hip or knee replacement. We tested them in the serious adverse event (SAE) tables of randomized trials on ClinicalTrials.gov. Methods. We included randomized drug trials with at least 500 participants. A language model classified arms from summaries without outcome counts (masked by instruction only). We pooled osteoarthritis-related SAEs by drug class as Mantel-Haenszel risk ratios (RRs). Because the plan followed a preliminary analysis of 72 trials, we report estimates rather than tests, checked by positive and negative controls and calibration. Results. The 881 placebo- or usual-care-controlled trials included 1.75 million participants and 9,408 osteoarthritis-related SAEs. The tables reproduced CANTOS's own canakinumab effect (RR 0.57, 95% CI 0.39 to 0.82), the anti-nerve growth factor excess (2.31, 1.82 to 2.92) and two of three modest effects specified before extraction: gallbladder disease with glucagon-like peptide-1 receptor agonists (GLP-1RAs; 1.36, 1.22 to 1.51) and ketoacidosis with sodium-glucose cotransporter-2 (SGLT2) inhibitors (1.96, 1.48 to 2.60). In the same trials, osteoarthritis-related SAEs did not differ detectably with GLP-1RAs (0.97, 0.86 to 1.10; calibrated 0.87, 0.54 to 1.41) or SGLT2 inhibitors (0.96, 0.82 to 1.12; calibrated 0.86, 0.53 to 1.40). Other proposed drugs gave imprecise estimates. Post hoc, 8 of 21 published observational estimates differed from randomized ones, in both directions (3 to 6 after calibration). Conclusions. Over about two years, GLP-1RAs and SGLT2 inhibitors had no detectable effect on osteoarthritis-related SAEs in trials that detected their known effects. Slow or modest structural effects remain possible.

Background: Recombinant (RIV) and cell culture-based inactivated (ccIIV) influenza vaccines could improve seasonal influenza prevention; however, evidence is limited in how protection may differ among non-egg-based vaccines. Methods: We conducted a randomized trial of RIV versus ccIIV to compare vaccine immunogenicity in adults aged 18 to 64 years during the 2024-25 influenza season (ClinicalTrials.gov, NCT06518577). Active surveillance for influenza-like illness was conducted for six months post-vaccination and cumulative incidence of influenza by vaccine type was compared to estimate relative vaccine efficacy. Participants were tested for influenza by reverse-transcription polymerase chain reaction or rapid antigen tests. Immunogenicity was evaluated by hemagglutination inhibition (HAI), virus microneutralization (MN), and neuraminidase inhibition (NAI) assays in a subset of blood specimens collected pre-vaccination and one-month post-vaccination. Results: Among the 591 participants, 25 cases of influenza A were detected; 2.4% cumulative incidence among RIV recipients versus 6.1% among ccIIV recipients. The probability of influenza was 61% lower with RIV than ccIIV (95% confidence interval: 7 to 84). Among 151 participants, post-vaccination HAI and MN titers vaccine components were higher among RIV recipients while NAI titers were higher among ccIIV recipients. Conclusions: RIV provided better protection than ccIIV against influenza A illness in adults during the U.S. 2024-2025 season.

Background: Rapid genome sequencing (rGS) is a first-tier test in the neonatal intensive care unit (NICU). Implementation strategies to scale rGS for clinical care may change clinician roles. We analyzed the NICU rGS workflow to understand challenges rGS poses for clinical roles and responsibilities. Methods: The study took a qualitative approach to understanding the rGS workflow in Level III and Level IV NICUs. The five workflow phases studied included: i) identification of a patient with a suspected genetic disorder, ii) subspecialist consultation, iii) test selection and ordering, iv) return of results, and v) disclosure. Data were collected via job task journals, interviews, and workflow diagram construction with clinicians involved in rGS. Analysis included participant-guided workflow diagram refinement, qualitative thematic analysis, and identification of rGS workflow challenges. Results: We documented issues related to decision-making authority and scope of responsibility for clinicians, with the majority relating to complexities of subspecialist consultations. Issues included differences in: criteria for triggering consultations, expectations of consulted subspecialists' roles, test selection preferences, and responsibility for documenting clinical interpretations and disclosure. Conclusion: Subspecialist consultations in clinical rGS involved significant role ambiguity and communication challenges, requiring intentional implementation efforts to ensure clear clinical roles and responsibilities.

Modern clinical medicine depends on reducing complex human realities into forms that support knowledge, judgment, and action. Such reduction is indispensable to scientific medicine, but necessarily selective. A medical framing may therefore remain well warranted within medicine while becoming insufficient in relation to the reality of a particular patient. What happens clinically when the adequacy of such a framing itself becomes uncertain remains insufficiently understood. We conducted an abductive, theory-generating qualitative study of 44 patients who attended a supplementary Dialogue-Based Outpatient Clinic within a breast oncology service in Japan between 2021 and 2023, comprising 111 consultations. The clinic had no predefined clinical agenda, allowing patients to raise concerns that mattered to them. Through iterative comparison within and across cases, we examined how patients' concerns were understood and responded to clinically. Across cases, a recurrent clinical process became apparent when patient reality called the adequacy of existing medical framing into question. Exploration of patients' concerns could expose a consequential mismatch between their reality and the framing through which medicine understands and represents clinical reality. Such mismatches prompted inquiry into medical framing to identify what required reopening. Reopening occurred when the identified framing, previously treated as provisionally settled, became reconsiderable in relation to the patient's reality. Reconsideration involved examining what had been reopened and exploring clinical responses through dialogue between clinician and patient, followed by a clinical response and provisional closure. We describe this recurrent process as Clinical Epistemic Reopening (CER). CER identifies a clinical process through which the framing produced by medicine's necessary selectivity in making complex reality clinically knowable and actionable can itself become reconsiderable when patient reality reveals its limits. CER can thereby reverse the usual direction of clinical scrutiny: aspects of medicine that ordinarily function as means of understanding and acting upon the patient can themselves become objects of clinical inquiry. CER thus allows medicine to remain open to patient reality beyond the limits of its existing framings.

Background: Ambient artificial-intelligence (AI) scribes are being deployed beyond medicine into allied-health practice, but comparative evidence mainly concerns physician documentation. Objective: To compare quality and transcript-grounded clinical-risk error burden of AI-generated and allied health professional notes from identical simulated consultations. Methods: Paired simulation across dietetics, physiotherapy, occupational therapy and speech and language therapy (five consultations each; 20 pairs; 40 notes). Heidi generated an unedited first-draft note and a professional documented each encounter. Professionals rated PDQI-9 quality. Professional and automated review identified unsupported statements and omissions; two language models graded clinical risk. Co-primary outcomes were PDQI-9 score and Critical+High error density. Results: Mean PDQI-9 scores were 38.45 and 35.05 for AI and professional notes (paired difference +3.40, 95% CI +0.01 to +6.79; Wilcoxon p=0.042; dz=0.47). The Bayesian estimate was +3.47 (94% equal-tailed credible interval +0.66 to +6.30; P[AI>professional]=0.989). Automated-reviewer all-error density was 3.35 vs 8.55 per note (professional-minus-AI difference 5.20, 95% CI 3.85 to 6.55); omission density was 1.45 vs 5.20 (difference 3.75, 2.80 to 4.65). Critical+High density was 0.35 vs 0.75 (difference 0.40, -0.10 to 1.00). The pooled quality result was driven principally by dietetics. Conclusions: AI-generated notes achieved modestly higher pooled quality and fewer transcript-grounded errors, chiefly omissions; serious-error evidence was inconclusive. Small discipline samples and incomplete ground truth preclude safety or discipline-wide superiority claims.

Objectives To describe active surveillance (AS) outcomes following introduction of an MRI-informed pathway, examine whether baseline PI-RADS/Likert scores identify men with earlier AS discontinuation, and assess the acceptability of dietary fibre supplementation in men on AS. Patients and methods We conducted a retrospective audit of 420 men enrolled in AS at Aberdeen Royal Infirmary between 2012 and 2022. Men were grouped into an MRI-informed pathway (n=198) or biopsy-first pathway (n=222). Time to AS discontinuation for any reason was analysed using Kaplan-Meier methods and log-rank tests. An exploratory analysis compared men with baseline PI-RADS/Likert scores of 4-5 and 2-3. Ten men on AS also completed semi-structured interviews analysed using the Theoretical Framework of Acceptability. Results Median follow-up was 3.1 years (IQR 1.6-5.1). Overall, 208 men (49.5%) discontinued AS, including 176 because of disease progression. Median time to discontinuation was 4.9 years (95% CI 4.4-5.6). It was shorter in the MRI-informed pathway than in the biopsy-first pathway (4.1 vs 5.6 years; log-rank p<0.01). Among 167 men with recorded baseline MRI scores, 44 (26.3%) had PI-RADS/Likert 4-5. Median time to discontinuation was 2.9 years in this group compared with 4.0 years for scores 2-3 (p<0.01). Interview participants were generally willing to consider dietary fibre supplementation, although gastrointestinal effects and study procedures were anticipated burdens. Conclusion AS discontinuation occurred earlier in the MRI-informed pathway, although differences in patient selection and surveillance practice should be considered when interpreting this finding. PI-RADS/Likert 4-5 identified a sizeable subgroup with earlier all-cause AS discontinuation that may help inform recruitment to future intervention studies. Dietary fibre supplementation was acceptable in principle, supporting further feasibility work.

Gestational diabetes mellitus (GDM) is associated with significant maternal and neonatal morbidity. Screening strategies vary internationally and the diagnostic performance of the 50g glucose challenge test (50g GCT) as a universal screening tool remains uncertain across diverse populations. This retrospective cohort study included 18,213 singleton pregnancies at a London tertiary hospital between 2010 and 2023. Women routinely underwent the universal two-step GDM screening pathway: a 50g GCT at 24 - 32 weeks' gestation, followed by a diagnostic 75-g oral glucose tolerance test if the 50g GCT result was greater than or equal to 7.8 mmol/L. We evaluated the use of universal two-step screening in detecting GDM, how its prevalence varies with maternal characteristics, including ethnicity, body mass index, age, and in those who would not have been included in risk factor-indicated screening, and the association between the 50g GCT and adverse outcomes. 2,015 women had an abnormal GCT, and 406 (20.1%) had an abnormal 75g OGTT, with GDM diagnosed at 24-28 weeks. We also found 87 women, despite a normal GCT and/or normal OGTT, developed late-onset GDM. The overall prevalence of GDM was 4.4% (810/18,213). Universal screening will therefore identify a significant number of GDM cases, notably including those in a low-risk cohort who would not have been screened using a risk factor-based approach. When we examined glucose as a continuous variable, there was an association between increasing 50g GCT values and adverse maternal and neonatal outcomes. Universal screening with a GCT is a feasible and safe approach and addresses a significant health disparity gap, in that women without risk factors are screened and may be diagnosed with GDM. Given the long-term cardiometabolic implications of GDM, pregnancy diagnosis is important to allow for longer-term targeting of cardiometabolic risk factors to improve long-term health screening for type 2 diabetes and obesity.

Importance: Conditions that are hard to diagnose, several more common in women, may be missing from electronic health records (EHRs), hiding patients from research cohorts and case finding. Objective: To measure how often the EHR contains a diagnosis code for chronic conditions that participants report, and to compare this with national survey benchmarks. Design, Setting, and Participants: This cross-sectional study used the All of Us Research Program Registered Tier Dataset v9. Participants were adults with EHR visits in both 12-month periods from July 2021 to June 2023 who completed a health history survey. We analyzed the data in October 2026. Exposures: Self-reported clinician diagnosis of 10 conditions with ongoing visits or treatment, as well as sex at birth, race and ethnicity, age, and years of EHR records. Main Outcomes and Measures: Share of participants reporting current care who had a qualifying diagnosis code, alone and relative to hypertension and type 2 diabetes, and the ratio of age-standardized coded shares to national survey prevalence. Results: Of 161,480 respondents, 114,610 (73,870 female [64.5%], median [IQR] age 63 [50-72] years) had at least 5 years of EHR records before the survey. Among those reporting current care, 84.6% (95% CI, 84.2%-85.0%) with hypertension and 87.0% (95% CI, 86.5%-87.6%) with type 2 diabetes had a code, compared with 41.3% (95% CI, 38.9%-43.8%) for endometriosis, 39.4% (95% CI, 34.3%-44.8%) for Lyme disease, and 24.4% (95% CI, 23.2%-25.6%) for chronic fatigue. Counting ICD-9-CM and other mapped codes, 55.3%, 51.5%, and 28.3%, respectively, had any qualifying record. Women had lower coded shares than men for hypertension, type 2 diabetes, obesity, depression, and anxiety (crude ratios 0.93-0.96, within-health-system ratios 0.98-1.02) and higher shares for migraine and fibromyalgia (within health systems, 1.11 [95% CI, 1.07-1.15] and 1.41 [95% CI, 1.29-1.57]). Age-standardized coded shares among active patients were 1.1 to 2.4 times national prevalence of the same self-reported diagnoses. Conclusions and Relevance: In this cross-sectional study, fewer than half of participants reporting ongoing care for chronic fatigue, Lyme disease, or endometriosis had a qualifying ICD-10-CM code. Linking each participant's report to their own record measured this gap directly.

Background: Vitamin D modulates innate and adaptive immunity and has been investigated for preventing pediatric respiratory infections. Objective: To assess the effects of vitamin D supplementation on respiratory tract infections (RTIs), including upper RTIs, lower RTIs/recurrent pneumonia, and hospitalization/clinical severity in children and adolescents. Methods: Systematic review and random-effects meta-analysis of 16 publications, of which 13 contributed to quantitative synthesis. Twenty-four effect estimates were pooled, eight per outcome. The odds ratio (OR) was analyzed on its natural logarithmic scale (logOR), using restricted maximum likelihood (REML) estimation and Knapp-Hartung (KH) adjusted inference. Where necessary, risk ratios (RRs), hazard ratios (HRs), and incidence rate ratios (IRRs) were approximated on the logOR scale. Results: For respiratory infection/upper RTI, pooled logOR was -0.284 (KH-adjusted 95% confidence interval [CI]: -0.678 to 0.110; OR 0.753; p = 0.132; I2 = 97.2%). For lower RTI/recurrent pneumonia, logOR was -0.445 (95% CI: -0.987 to 0.097; OR 0.641; p = 0.093; I2 = 89.5%). For hospitalization/clinical severity, logOR was -0.609 (95% CI: -1.134 to -0.083; OR 0.544; p = 0.029; I2 = 78.3%). Conclusions: Pooled estimates favored supplementation in direction for all three groups, although confidence intervals included the null for the first two. Heterogeneity was substantial, and the results are limited by approximations among effect measures, clinically diverse endpoints, and potentially correlated effects from individual studies.

Background. Lead crosses the placenta and harms the developing brain, and no safe level is known. Bangladesh lacks national estimates of lead exposure in pregnancy. Objectives. We estimated blood lead in pregnant women nationally, described where and in whom it was raised, and examined links with child lead and haemoglobin. Methods. In the Bangladesh Multiple Indicator Cluster Survey 2025, 1,932 of 2,711 eligible pregnant women (71%) had valid venous blood results. Survey-weighted modified Poisson models estimated prevalence ratios (PR) for blood lead of 3.5 microgram/dL or more, an analytical cut-off. We also studied 540 households with a tested child aged 12 to 59 months. Results. Among tested women, geometric mean blood lead was 2.05 microgram/dL (95% CI 1.99 to 2.12). In all, 17.7% (15.7 to 19.9) had 3.5 microgram/dL or more and 7.6% (6.1 to 9.3) had 5 microgram/dL or more. Greater Dhaka, defined after inspecting district estimates, held 12% of pregnant women but 64% (54 to 73) of those at 5 microgram/dL or more. The richest quintile had a crude PR of 3.06 (2.02 to 4.63, P<0.001), attenuated to 1.09 (0.72 to 1.67, P=0.678) after adjustment for place. No clear association was seen with cosmetics, indoor smoking or nearby battery sites. A woman's lead of 3.5 microgram/dL or more was associated with child lead of 5 microgram/dL or more (adjusted PR 1.50, 1.16 to 1.96, P=0.002). This cut-off identified only 23% (16 to 30) of them. Conclusions. Raised blood lead in pregnancy varied sharply by place and was highest in greater Dhaka. The crude wealth association was markedly attenuated after adjustment for place. Maternal lead was linked with child lead, but most exposed children lived with women below the cut-off. These findings support source investigation in greater Dhaka and evaluation of targeted lead assessment for women and children.

Summary Background We used sequential target trial emulation (TTE) to examine associations between opioid analgesic initiation and adverse maternal and neonatal outcomes while accounting for gestational timing, time at risk, and potential confounding. Methods Using the Early Life Course platform, comprising linked population-based data for births in New South Wales, Australia (2013-2019), we emulated a new trial at each gestational week, comparing women who initiated a prescribed opioid analgesic with eligible non-initiators. Baseline covariates were balanced using inverse probability weighting. Weighted logistic regression estimated odds ratios (ORs) for neonatal outcomes, postpartum haemorrhage, and severe maternal morbidity. Pooled logistic regression estimated hazard ratios (HRs) for other maternal outcomes, combined across gestational weeks using fixed-effects meta-analysis. Sensitivity analyses assessed unmeasured confounding, exposure misclassification, and potential reverse causation. Findings Among 511,357 pregnancies, over 80% of opioid initiators received only one dispensing. Opioid initiation was not associated with increased risks of placental abruption (HR 0.94, 95% CI 0.75-1.16), severe maternal morbidity (OR 1.05, 0.97-1.11), postpartum haemorrhage (OR 0.98, 0.95-1.02), low Apgar score (OR 0.99, 0.87-1.08), small for gestational age (OR 0.90, 0.85-0.95), or neonatal abstinence syndrome (OR 0.98, 0.72-1.30). Risks were elevated for PPROM (HR 1.10, 0.98-1.23), preterm birth (HR 1.26, 1.19-1.33), severe neonatal morbidity (OR 1.08, 1.02-1.17), and perinatal death (OR 1.29, 1.10-1.52). Perinatal death estimates attenuated in analyses addressing potential reverse causation. Interpretation Using a TTE approach that accounted for gestational timing and time at risk, we found no appreciable increase in most maternal or neonatal outcomes following predominantly short-term opioid initiation. Elevated risks of preterm birth, perinatal death, and third-trimester PPROM may reflect causal effects or confounding by pregnancy-related indications. Studies using time-appropriate designs and detailed information on prescribing indications and their timing are needed to clarify these associations.